Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHARM > Atherosclerosis and lipoprotein metabolism > Flashcards

Atherosclerosis and lipoprotein metabolism Flashcards

1
Q

Atherosclerosis=

A

Atherosclerosis= the build up of a
waxy plaque on the inside of
blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Atherogensis=

A

Atherogensis= formation of
abnormal fatty or lipid masses in
arterial walls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

main risk factor of atherosclerosis and atherogenesis

A

high blood cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

High Blood Cholesterol
* Estimated _____ million adults ≥ 20YO have TC ≥ _____
* New Cholesterol guidelines in 2018:
* Focused on?
* primary treatment to reduce cholesterol?
* Very high risk patients may need?

A

High Blood Cholesterol
* Estimated 28.5 million adults ≥ 20YO have TC ≥ 240mg/dL (High)
* New Cholesterol guidelines in 2018
* Focused on identifying high risk and very high risk patients
* Statins are the primary treatment to reduce cholesterol
* Very high risk patients may need combination therapy to reach LDL ≤ 70mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

lipoproteins of interest

A

chylomicrons, LDL, HDL, VLDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  • Chylomicrons

% TG % pro

A
  • Highest proportion of triglycerides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  • VLDL

%TG %chol %pro

A
  • Very Low Density Lipoprotein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  • LDL

%TG %chol %pro

A
  • Low Density Lipoprotein
  • “Bad Cholesterol”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  • HDL

%TG %chol %pro

A
  • High Density Lipoprotein
  • “Good Cholesterol”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

lipoprotein density scale

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Optimal Cholesterol Levels:
* Total Cholesterol
* HDL
* LDL
* Triglycerides

A
  • Total Cholesterol: ≤ 200mg/dL
  • HDL: ≥ 60mg/dL
  • LDL: ≤ 100mg/dL
  • Triglycerides: ≤ 150mg/dL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Friedewald Formula

A

less predictive with TG>400

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Risk Factors for ASCVD

A
  • Smoking
  • Hypertension
  • Hyperlipidemia: increased LDL and TC/ decreased HDL
  • Diabetes mellitus
  • Age (men ≥45 yo, women ≥55yo)
  • Obesity
  • Physical Inactivity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

multiple risk factor effects

A

additive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ASCVD Risk Assessment

risk factors included? estimates? used to guide?

A

ASCVD Risk Score can be calculated with online tool
* Risk Factors used include: age, gender, total and HDL cholesterol, smoking status, blood pressure, diabetes,
and race
* Estimates 10-year risk of MI or stroke
* Used to guide lipid therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

No need to calculate ASCVD score if patient has?

A

No need to calculate ASCVD score if patient has Clinical ASCVD
Clinical ASCVD:
* Established Coronary Artery Disease (CAD)
* History of stroke or TIA
* Peripheral Artery Disease (P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

atherogenesis steps

HDL involvment?

A
  1. Endothelial dysfunction
  2. Endothelial injury
  3. LDL deposits into vessel wall
  4. Formation of foam cells (Macrophages filled with LDL)
  5. Fatty Streak
  6. Inflammation (Smooth muscle growth)
  7. Fibrous cap over lipid core

at steps 3-5 HDL may remove cholesterol from vessel walls (The process of HDL mobilizing cholesterol and transporting back to the liver is called ‘reverse cholesterol transport)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

normal Aa with athersclerosis

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

status of plaque and pt symptoms

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Lipoprotein metabolism
* Exogenous pathway

A
  • Cholesterol and TG absorbed from diet transported as chylomicrons to muscle and adipose tissue
  • Chylomicrons metabolized by lipoprotein lipase to release TG
  • Chylomicron remnants (mostly cholesteryl esters) return to the liver
  • Cholesterol in liver may be:
    1) stored
    2) turned into bile, or
    3) enter endogenous pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Lipoprotein metabolism
* Endogenous pathway

A
  • Cholesterol and TG made in liver leave as VLDL
  • VLDL metabolized by lipoprotein lipase to release TG- VLDL becomes LDL
  • LDL provides cholesterol source for cells to make cell membranes- also atherogenesis
  • Cell use an LDL-receptor to take up LDL
  • Liver releases HDL to collect cholesterol and return to liver (reverse cholesterol transport)
  • Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesterol to HDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

HMG-CoA reductase inhibitors (Statins)
Mechanism of Action

A
  • Inhibit HMG-CoA reductase
  • Rate-limiting step in endogenous cholesterol production
  • Also induce an increase in hepatic LDL receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

HMG CoA inhibitor names

A

all end in -statin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

HMG-CoA reductase inhibitors (Statins)
Effects on Lipid parameters

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

HMG-CoA reductase inhibitors (Statins)
Relative potency

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

high intensity statins

A

Atorvastatin 40-80mg
Rosuvastatin 20-40mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

HMG-CoA reductase inhibitors (Statins) Clinical benefits for primary prevention
* Target age? LDL?
* Use what to guide therapy?
* >7.5% to ≤ 20% risk?
* > 20% risk?
* helpful test?
* Diabetes?

A
  • Target age 40-75 YO with LDL 70- 189mg/dL
  • Use ASCVD risk score to guide therapy
  • > 7.5% to ≤ 20% risk= moderate intensity statin
  • > 20%- high intensity statin
  • Coronary Calcium Score helpful
  • Diabetes: All patients get at least moderate intensity statin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

HMG-CoA reductase inhibitors (Statins) Clinical benefits secondary prevention
* All patients that are?
* intensity statin?
* Very-high risk consider?

A
  • All patients under 75 YO with established ASCVD
  • High intensity statin
  • Very-high risk consider combo therapy if LDL > 70mg/dL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

HMG-CoA reductase inhibitors (Statins) Pleiotropic effects Positive:
* Plaque?
* inflamm?
* endothelial function?
* platelets?
* neovascularization?

A
  • Plaque stabilization
  • Reduced inflammation
  • Improved endothelial function
  • Reduced platelet aggregability
  • Increased neovascularization of ischemic tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

HMG-CoA reductase inhibitors (Statins)
Pleiotropic effects* Negative/Neutral:
pregnancy?
immune?

A
  • Inhibition of germ cell migration during development (Pregnancy contraindication)
  • Immune suppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

HMG-CoA reductase inhibitors (Statins)
Adverse Drug Reactions & Contraindications

A
32
Q

HMG-CoA reductase inhibitors (Statins) Drug-Drug Interactions
* Many DDI due to?
* Impaired statin metabolism→?
* Impaired clearance of competing drug →?
* Pravastatin and Rosuvastatin?

A
  • Many DDI due to hepatic metabolism (via CYP450 3A4 or PgP)
  • Impaired statin metabolism→ increased risk of hepatotoxicity or myopathy
  • Impaired clearance of competing drug → increased risk of competing drug ADRs
  • Pravastatin and Rosuvastatin are not significantly cleared via CYP450 and have the least amount of DDI of this type
33
Q

Impaired statin absorption → ?

what can cause this?

A

Impaired statin absorption → decreased statin efficacy
* Example: Bile acid binding agents

34
Q

statin Increased risk of myopathy from interaction?

A

Increased risk of myopathy (pharmacodynamics interaction)
* Other drugs that also have a risk of myopathy (ex. Fibrates)

35
Q

atorvastatin ADRs

A
  • ADRs: Elevated liver enzymes(hepatotoxicity), myopathy, rhabdomyolysis
  • Pregnancy category: X (contraindicated)
36
Q

atorvastatin drug interactions
* Increased risk of myopathy with?
* Increased effects of?

A
  • Increased risk of myopathy with erythromycin, ketoconazole, itraconazole
  • Increased effects of midazolam when used in combination
37
Q

atorvastatin dental

A

Dental implications: Myopathy may present as weakness with chewing or brushing teeth

38
Q

Atorvastatin
* MOA:

A
  • MOA: HMG-CoA reductase inhibitor
39
Q

PCSK-9 Inhibitors Mechanism of Action

A
  • Block the action of proprotein subtilisin kexin type 9 (PCSK9)
  • PCSK-9 promotes the degradation of LDL receptors
  • Inhibition of PCSK-9 results in more active LDL receptors and
    lower serum LDL
40
Q

PCSK-9 Inhibitors names

A

Alirocumab
Evolocumab

41
Q

PCSK-9 Inhibitors
Effects on Lipid parameters (TC, LDL, TG, HDL)

A
42
Q

PCSK-9 not common why?

A

PCSK-9 inhibitors are given by SQ injection
Cash price was $14,500/year in 2018 price was  60% to ~$5,800/year

43
Q

Alirocumab
* MOA
* Dental implications

A
  • MOA: Binds to proprotein subtilisin kexin type 9 (PCSK9).
    Preventing PCSK9 from binding LDL receptors, thereby
    promoting LDL degretation within the liver
  • Dental implications: none
44
Q

alirocumab ADRs

A

Injection site reactions, diarrhea, decreasing LDL too low

45
Q

alirocumab interactions

A

none of dental significance

46
Q

ATP-citrate lyase (ACL) inhibitor

A

Bempedoic acid (Nexletol®) only drug in class
* Inhibit cholesterol synthesis two -steps ahead of statins (HMG- CoA reductase inhibitors)
* Approved by the FDA in February 2020
* Not addressed in clinical guidelines

47
Q

Bempedoic acid
Effects on Lipid parameters (TC, TG, LDL, HDL)

A
48
Q

Bempedoic acid and ezetimibe

A

Synergistic LDL lowering when combined with ezetimibe therapy

49
Q

Bempedoic acid
* MOA
* Drug-Drug interactions:
* Dental implications:

A
  • MOA: Inhibit cholesterol synthesis two-steps ahead of statins
  • Drug-Drug interactions: None of significance to dentistry
  • Dental implications: none
50
Q

bempedoic acid ADR

A

Elevated uric acid, back pain, elevated liver enzymes

51
Q

Inhibitors of cholesterol absorption names

A

(Ezetimibe and Bile acid binding agents )
Absorption inhibitors:
* Ezetimibe
* Ezetimibe/Simvastatin
Bile acid binding agents:
* Cholestyramine
* Colesevelam
* Colestipol

52
Q

Ezetimibe
Mechanism of Action

A
  • Blocks cholesterol absorption in the intestine
    (duodenum)
  • Blocking transport protein NPC1L1 in the brush border of the enterocyte
  • Does not affect absorption of fat-soluble vitamins, triglycerides, or bile acid
53
Q

Ezetimibe
Effects on Lipid parameters

A
54
Q

Ezetimibe synergestic with?

A

statins, can lower LDL synergistically

55
Q

Ezetimibe
* MOA:
* Drug-Drug interactions:
* Dental implications:

A
  • MOA: Blocks absorption of cholesterol in the intestine by blocking the NPC1L1 transport protein
  • Drug-Drug interactions: None of significance to dentistry
  • Dental implications: none
56
Q

ezetimibe ADRs

A

Rare- maybe back pain or diarrhea

57
Q

Bile Acid Binding Agents
Mechanism of Action

A
  • Bind to bile acid in the intestine
  • Prevent resorption of bile acid
  • Result in increase uptake of LDL by liver
58
Q

Bile Acid Binding Agents
Effects on Lipid parameters

A

can actually raise Tg

59
Q

Colesevelam
* MOA:

A

Bile acid binder
* MOA: Binds bile acid preventing resorption

60
Q

colesevelam ADRs

A

Mainly GI distress- constipation, abdominal pain, nausea, dyspepsia

61
Q

coleveselam interactions

A
  • Drug-Drug interactions: None of significance to dentistry
  • Many others due to inhibition of absorption of medications
  • Take 1 hour before or 2 hours after other medication
62
Q

Bile Acid Binding Agents
Example: Colesevelam-Dental Implications

A
  • Consider semisupine chair position for patient comfort due to GI side effects of medication
63
Q

Fibrates Mechanism of Action

A
  • Complex mechanism of action
  • Agonist of PPARα nuclear receptor
  • Increase transcription of lipoprotein lipase= Marked decrease in VLDL and triglycerides
  • Also increase LDL uptake and HDL synthesis
64
Q

fibrate names

A

FenoFIBrate
FenoFIBric Acid
GemFIBrozil

65
Q

Fibrates
Effects on Lipid parameters

A

mainly target Tg

66
Q

Fenofibrate
* MOA:

  • Drug-Drug interactions:
A
  • MOA: PPARα nuclear receptor agonist increasing lipoprotein lipase levels
  • Drug-Drug interactions: None of significance to dentistry
67
Q

fenofibrate ADRs

A

Myopathy
dyspepsia
blurred vision/eye floaters
elevations in liver enzymes
GI distress
* Increase r/o ADRs when combined with statin

68
Q

Fibrates
Example: Fenofibrate-Dental Implications

A
  • Consider semisupine chair position for patient comfort due to GI side effects of medication
  • Avoid dental light in patient’s eyes; offer dark glasses for patient comfort due to vision side effects
  • May cause dry mout
69
Q

Nicotinic acid or its derivatives
Mechanism of Action

A
  • Inhibits hepatic VLDL secretion
  • Lowers serum Triglycerides and LDL
  • Increases serum HDL
70
Q

Niacin
Effects on Lipid parameters

A

Dose of lipid lowering effects 500mg-2000mg daily, much higher than daily vitamins

71
Q

Niacin Adverse Drug Reactions
* Flushing? counter?
* GI?
* Liver?
* glucose?
* gout?

A
  • Flushing: Reduced by taking aspirin 30 minutes before dose
  • Gastrointestinal distress: Nausea, vomiting, or diarrhea
  • Liver damage/dysfunction (increased liver enzymes), Can occur at any time during therapy
  • Impaired glucose tolerance: Can worsen a patient’s control of diabetes
  • Precipitate gout flare: increased circulating uric acid level
72
Q

Niacin
* MOA:
* Drug-Drug interactions:

A
  • MOA: Inhibits synthesis of VLDL
  • Drug-Drug interactions: None of significance to dentistry
73
Q

niacin dental implications

A
  • Dental implications: Minor- may cause dizziness so be careful when standing up, May increase risk of bleeding
74
Q

niacin ADRs

A

flushing
GI distress
Liver dysfunction
glucose intolerance
gout flare
* Increased risk of hepatotoxicity when combined with statin

75
Q

Most potent
medication for
LDL lowering?

A

PCSK9 inhibitors: Alirocumab, Evolocumab

76
Q

what medication class could raise TG’s?

A

Bile Acid Binding Agents: Cholestyramine, Colesevelam, Colestipol

PHARM (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions